Skip to content
Cultural Foundation
Author:
Amplia Therapuetics Limited
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
August 4, 2026
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
July 31, 2026
Amplia Announces Publication of New FAK Inhibitor Patent Application
July 9, 2026
Amplia Announces Appointment of Brett Carter to Board
July 7, 2026
Amplia Announces Changes to Board’s Leadership Roles
July 6, 2026
Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
June 22, 2026
Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
May 19, 2026
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
May 8, 2026
Accent Trial Mature Data Presented at International Conference
April 24, 2026
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
March 26, 2026
1
2
Next Page
→